Table 3 The comparison of AE between case and control groups.

From: Apatinib Mesylate in the treatment of advanced progressed lung adenocarcinoma patients with EGFR-TKI resistance —A Multicenter Randomized Trial

AE Grade

Case (n = 39)

Control (n = 29)

1–2

3–4

n (%)

1–2

3–4

n (%)

Hypertension

11

4

15 (38.5)

2

0

2 (6.9)

Hand-foot syndrome

15

3

18 (46.2)

6

1

7 (24.1)

Proteinuria

4

3

7 (18)

0

0

0

Fatigue

5

5

10 (25.6)

0

3

3 (10.3)

Lung infection

1

0

1 (2.6)

1

0

1 (3.4)

Bone marrow suppression

1

0

1 (2.6)

1

0

1 (3.4)

Oral ulcer

2

0

2 (5.1)

1

0

1 (3.4)

Cough

1

0

1 (2.6)

0

0

0

Bilirubin increase

1

0

1 (2.6)

1

0

1 (3.4)

Thrombocytopenia

1

0

1 (2.6)

1

0

1 (3.4)

Bleeding

4

2

6 (15.4)

1

0

1 (3.4)

Gastrointestinal reaction

1

0

1 (2.6)

27

0

27 (93.1)

Anemia

2

0

2 (5.1)

1

0

1 (3.4)

Serious AE rate

13 (33.3)

4 (13.8)

Total AE rate

35 (89.7)

28 (96.6)

Back to article page